Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Melanoma is an aggressive skin cancer with limited treatment options.
• Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
• Gene therapy offers a novel approach to target tumor growth by delivering therapeutic genes.

Purpose of the Study:

• To investigate the efficacy of local and systemic delivery of the angiostatin gene for inhibiting human melanoma growth in vivo.
• To evaluate the anti-angiogenic effects of angiostatin gene therapy on melanoma.
• To assess the potential of liposome-mediated gene delivery for melanoma treatment.

Main Methods:

• Nude mice were transplanted with human melanoma cells.
• Liposome-coated plasmids encoding murine and human angiostatin (CMVang and BSHang) were administered weekly, either locally or systemically.
• Control groups received liposome-coated plasmids with the lacZ gene or no treatment.
• Tumor growth, DNA presence, gene expression, apoptosis, and vessel density were analyzed.

Main Results:

• Angiostatin gene therapy reduced melanoma growth by 50%–90% compared to controls.
• Both local and systemic (intraperitoneal) delivery suppressed tumor growth, indicating a systemic effect.
• Tumor growth suppression and delayed onset of tumor growth were observed.
• Increased apoptosis and reduced vessel density were noted in treated tumors.
• Lipofected DNA was detected in tissues, and angiostatin expression was confirmed.

Conclusions:

• Systemic, liposome-mediated delivery of angiostatin genes is a promising strategy for inhibiting melanoma growth.
• Angiostatin gene therapy demonstrates anti-angiogenic effects, leading to melanoma suppression.
• This approach warrants further investigation for human melanoma treatment.